Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4

Espana, B; Joseph-Tornabène, F; Jaquet, Cécile; Perrot, S; Prouillac, C

Abstract

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4

Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C

Issue: Jul/Aug 2020 - Volume 24, Number 4

View All Articles in Issue

Page(s): 327-336

Download in electronic PDF format for $75

Note: Electronic version includes errata or revisions.

Abstract

Extemporaneous compounding in veterinary practice sometimes represents the only possibility for treating animals in the absence of appropriate commercial formulations, especially for particular species. This method involves manipulating pharmaceutical active ingredients to a suitable dosage and formulation for administration to humans or animals. However, veterinarians and pharmacists should focus on the risk of potential incompatibilities and instability of their preparations. To help practitioners in drug compounding, we investigated the stability of oral suspensions of tramadol, fluoxetine, and doxycycline in a commercial ready-to-use vehicle (SyrSpend). A validated high-performance liquid chromatography method was developed to assay these active pharmaceutical ingredients. The oral suspensions were prepared at two concentration ranges and were stored in amber glass bottles under refrigerated conditions and at room temperature. After 90 days, the average recovery rates were between 90% and 110% for tramadol (5 mg/mL to 30 mg/mL) and doxycycline (2 mg/mL to 10 mg/mL) without organoleptic modification. For fluoxetine, only the formulation at 2 mg/mL was stable; at higher concentrations, the uniformity of the suspension was compromised.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2020 Pg. 327-336	Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Mar/Apr 2003 Pg. 106-113	Veterinary Transdermal Medications: A to Z Author(s): Davidson Gigi S
May/Jun 2023 Pg. 234	Doxycycline 166.7-mg/mL Oral Suspension (Veterinary) Author(s): Allen Loyd V Jr
Nov/Dec 2006 Pg. 418	Case Report: Transdermal Fluoxetine as Therapy for Feline Anxiety Author(s): Fields Shannon W
May/Jun 2017 Pg. 242-246	Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Author(s): Eichstadt Lauren R, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E
Jul/Aug 2020 Pg. 321	Tramadol Hydrochloride 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Sep/Oct 2015 Pg. 428-431	Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures Author(s): Nahata Milap C
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Mar/Apr 2004 Pg. 156-159	Effect of Freezing, Long-Term Storage and Microwave Thawing on the Stability of Tramadol in 5% Dextrose Infusion in Polyvinyl Chloride Bags Author(s): Lebrun John, Hecq Jean-Daniel, Vanbeckbergen Danielle, Jamart Jacques, Galanti Laurence M
Sep/Oct 2021 Pg. 412	Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 503	Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2022 Pg. 140	Alprazolam 1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2017 Pg. 491	Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2004 Pg. 10-14	Women's Oral Health: Is There a Hormonal Link? Author(s): Preckshot John
May/Jun 2010 Pg. 182-192	Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
Jan/Feb 2004 Pg. 46-48	Basics of Compounding for Disorders of the External Ear Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 493	Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 494	Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 492	Clonazepam 0.2 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2018 Pg. 148	Lamotrigine 1-mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr